欧洲乳腺X线筛查降低乳腺癌特异性死亡率的系统评价证据
该系统评价检索6个数据库至2018年3月,纳入60项研究(36项队列、17项病例对照、7项RCT),评估欧洲组织性乳腺X线筛查对乳腺癌死亡率的影响。高质量研究显示,参加筛查者较未参加者乳腺癌死亡率降低幅度为北欧33%-43%、南欧43%-45%、西欧12%-58%;受邀者较未受邀者降低4%-31%。东欧缺乏定量证据,估计值差异大反映评价设计不同而非筛查效果差异。
要点
- 参加筛查者较未参加者乳腺癌死亡率降低33%-45%(北欧/南欧高质量研究)。
- 受邀筛查者较未受邀者乳腺癌死亡率降低4%-31%,效果估计因设计而异。
- 东欧缺乏组织性筛查对乳腺癌死亡率影响的定量证据。
核心结论
- 系统评价提供证据表明,在已实施并监测组织性筛查的欧洲地区,筛查可降低乳腺癌死亡率,但东欧仍缺乏定量评估。
研究设计与样本
- 系统评价检索Embase、Medline和Web of Science等6个数据库至2018年3月,纳入随访至少5年的英文原始研究,包括RCT或观察性研究。
- 最终纳入60项研究:36项队列研究、17项病例对照研究和7项RCT,无来自东欧的研究。
主要发现
- 在质量很好或良好的研究中,参加筛查者较未参加者的乳腺癌死亡率降低幅度为:北欧33%-43%,南欧43%-45%,西欧12%-58%。
- 受邀筛查者较未受邀者的乳腺癌死亡率降低幅度为4%-31%。
临床怎么用
- 在已实施组织性乳腺X线筛查的欧洲地区,筛查与乳腺癌死亡率降低相关,支持继续开展并监测组织性筛查。
- 解读筛查效果时应考虑研究设计差异,参加筛查与受邀筛查的死亡率降低幅度不同。
局限性
- 缺乏来自东欧的研究,该地区无法定量评估筛查对乳腺癌死亡率的影响。
- 各研究估计值范围宽,反映评价设计差异较大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to quantify the impact of organised mammography screening on breast cancer mortality across European regions. Therefore, a systematic review was performed including different types of studies from all European regions and stringently used clearly defined quality appraisal to summarise the best evidence. METHODS: Six databases were searched including Embase, Medline and Web of Science from inception to March 2018. To identify all eligible studies which assessed the effect of organised screening on breast cancer mortality, two reviewers independently applied predefined inclusion and exclusion criteria. Original studies in English with a minimum follow-up of five years that were randomised controlled trials (RCTs) or observational studies were included. The Cochrane risk of bias instrument and the Newcastle-Ottawa Scale were used to assess the risk of bias. RESULTS: Of the 5015 references initially retrieved, 60 were included in the final analysis. Those comprised 36 cohort studies, 17 case-control studies and 7 RCTs. None were from Eastern Europe. The quality of the included studies varied: Nineteen of these studies were of very good or good quality. Of those, the reduction in breast cancer mortality in attenders versus non-attenders ranged between 33% and 43% (Northern Europe), 43%-45% (Southern Europe) and 12%-58% (Western Europe). The estimates ranged between 4% and 31% in invited versus non-invited. CONCLUSION: This systematic review provides evidence that organised screening reduces breast cancer mortality in all European regions where screening was implemented and monitored, while quantification is still lacking for Eastern Europe. The wide range of estimates indicates large differences in the evaluation designs between studies, rather than in the effectiveness of screening.
引用
- Zielonke N, Gini A, Jansen EEL, et al. Evidence for reducing cancer-specific mortality due to screening for breast cancer in Europe: A systematic review. Eur J Cancer. 2020. PMID: 31932175. doi:10.1016/j.ejca.2019.12.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。